3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
CNS
2
Conditions
Prostatic Neoplasms
12
Brain Neoplasms
3
Urogenital Diseases
2
Neoplasms
2
Disease
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Neoplasm Metastasis
1
Metastatic Castration-resistant Prostate Cancer
1
Carcinoma, Transitional Cell
1
Carcinoma, Lobular
1
Interventions
fluciclovine F-18
2
Positron-Emission Tomography
2
Injections
2
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
2
pembrolizumab
1
ioflupane
1
idelalisib
1
aflibercept
1
Water
1
Vertical Dimension
1
Methylene Blue
1
Mammography
1
Drug Delivery Systems
1
Diagnosis, Computer-Assisted
1
Daunorubicin
1
Cytarabine
1
Control Groups
1
CPX-351
1
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Has results
×
Disease
×
fluciclovine F-18
×
Clear all
NCT04410133
2025-08-28
REVELATE
Blue Earth Diagnostics
Phase 3
Completed
151 enrolled
29 charts
NCT04410367
2025-07-20
PURSUE
Blue Earth Diagnostics
Phase 2
Completed
23 enrolled
10 charts